Search

Displaying results 1231 - 1240 of 4207 in total
  1. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  2. Drug

    Propyl alcohol

    go.drugbank.com/drugs/DB03175
    Approved

    A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.

  3. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available. … [L2615] Dandruff is a common scalp disease affecting >40% of the world's adult population, and may be caused by fungi such as _Malassezia globosa_ and _M. restricta_.[A32162]

  4. Drug

    Hydromorphone

    go.drugbank.com/drugs/DB00327
    ApprovedIllicitInvestigational

    [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]

  5. Drug

    Varicella zoster vaccine (live/attenuated)

    go.drugbank.com/drugs/DB10318
    ApprovedInvestigational

    This is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% [A31349]. … First approved in May 2006 by the Food and Drug Administration, Zostavax was the first vaccine available for the prevention of shingles.

  6. Drug

    Cilostazol

    go.drugbank.com/drugs/DB01166
    ApprovedInvestigational

    It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

  7. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Some of their side effects are also caused by actions in the CNS.

  8. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production. … Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity.

  9. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells. … [L45698,A258488] Glofitamab was approved by Health Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20

  10. Drug

    Tenofovir disoproxil

    go.drugbank.com/drugs/DB00300
    ApprovedInvestigational

    Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name _Viread_, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase